P200030/S026: GORE EXCLUDER Conformable AAA Endoprosthesis
FDA’s recorded scope: removal of UV adhesive application onto the guidewire extension tube via the hypotube assembly during manufacturing of the GORE EXCLUDER Conformable AAA Endoprosthesis
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 5 FDA records to the applicant name W. L. Gore and Associates, Inc.. 3 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 29, 2025 to Jul 29, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MIH appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P200030, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 32360 N. N. Valley Pkwy., Phonix, AZ, 85085. Recorded on P200030/S026, decision dated Jul 29, 2026.
System, Endovascular Graft, Aortic Aneurysm Treatment.
FDA’s recorded scope: removal of UV adhesive application onto the guidewire extension tube via the hypotube assembly during manufacturing of the GORE EXCLUDER Conformable AAA Endoprosthesis
FDA’s recorded scope: Approval for modification to the 2nd deployment fiber used in the delivery system for the GORE EXCLUDER Conformable AAA Endoprosthesis, GORE EXCLUDER AAA Endoprosthesis, and GORE EXCLUDER Iliac Branch Endoprosthesis devices
FDA’s recorded scope: Approval to remove a warning from the device labeling regarding lack of safety and effectiveness data on the use of your device in treatment of ruptured aneurysms, as well as a brief summary of the supportive data with regard to treatment of ruptured aneurysms.
FDA’s recorded scope: Approval for modification of the primary sewn tubular sleeve manufacturing process, a change to the primary sleeve attachment fiber, and a change to the proximal primary sleeve attachment pattern for the GORE EXCLUDER Conformable AAA Endoprosthesis.
FDA’s recorded scope: a manufacturing facility move for a supplier of delivery system components for the GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CMDS) and GORE EXCLUDER Conformable AAA Endoprosthesis (EXCC)
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.